None
Quote | Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE:TAK)
Last: | $13.27 |
---|---|
Change Percent: | -0.76% |
Open: | $13.29 |
Close: | $13.27 |
High: | $13.31 |
Low: | $13.21 |
Volume: | 1,033,508 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
News | Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE:TAK)
2024-05-02 12:28:33 ET Summary EXEL continues to successfully implement Farallon's restructuring suggestions. A pivotal decision on cabo's current patent litigation is due by end of 1H'24. Multiple billions of potential revenue are at stake. I'm not holding shares through the ...
2024-05-01 09:00:00 ET Summary April 2024 jobs report expected to show an increase of 250,000 jobs, indicating continued tightness in the labor market. Healthcare sector likely to add jobs, while drug manufacturers may struggle. Construction, government, energy, and beverage i...
Message Board Posts | Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE:TAK)
Subject | By | Source | When |
---|---|---|---|
Just saying, | Boing x 2 | investorshub | 01/31/2023 6:08:12 PM |
Takedas Pipeline Has Potential to Contribute Significantly to | Phosphene | investorshub | 12/09/2020 4:21:27 AM |
Japan's Takeda eyes new focus on vaccines after | Phosphene | investorshub | 11/29/2020 11:24:36 PM |
MIT-Takeda program launches | Phosphene | investorshub | 11/29/2020 11:22:36 PM |
Takeda shares tumbled as much as 9.3 percent | rising | investorshub | 05/08/2018 1:19:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Takeda Pharmaceutical Company Limited American Depositary Shares Company Name:
TAK Stock Symbol:
NYSE Market:
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion Based on Results from a Phase 3 Clinical Trial Which Demonstrated Significan...
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — ...
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...